NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today said that it raised $4.2 million in its Series D round. The Pittsfield, Mass.-based company added that it plans to close the $5 million round on May 31.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: role for epigenetic in neuronal excitability, and more.
The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.
Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.
A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.